SURPASS-6 (A study of tirzepatide (LY3298176) versus insulin lispro (U100) in participants with type 2 diabetes inadequately controlled on insulin glargine (U100) with or without metformin; ClinicalTrials.gov identifier: NCT04537923): assesses the effect of the addition of tirzepatide weekly versus insulin lispro (U100) three times daily in patients with T2D prescribed insulin glargine (U100) with or without metformin. Here, INS is linked to type 2 diabetes mellitus.